We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Danish pharmaceutical company Lundbeck has signed an agreement to secure the rights of biotech firm ImmunoBrain Checkpoint’s (IBC) breakthrough research in Alzheimer's disease treatment.